News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NewGen Therapeutics to Present Data for NT113, a Potent Irreversible Pan-erbB Inhibitor, at the American Association for Cancer Research Meeting


4/4/2013 6:36:42 AM

NewGen Therapeutics, Inc. today announced that it will present an abstract entitled “NT113, A Potent and Selective Pan-erbB inhibitor, is Efficacious in Vivo and Has High Brain Penetrance” at the American Association of Cancer Research Meeting (AACR), being held April 6-10, 2013 in Washington, D.C.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES